REDWOOD CITY, Calif.--(BUSINESS WIRE)--Pathwork Diagnostics, Inc., a privately held molecular diagnostics company focused on oncology, announced that results of a study demonstrating the capability of its Pathwork® Tissue of Origin Test to be performed on a variety of body fluid specimens were published online in the peer-reviewed journal Cancer Cytopathology. The Tissue of Origin Test aids in the diagnosis of challenging cancer cases such as those that are metastatic or that have a complex clinical history and is used by leading clinicians around the country.
